Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor

This publication has 33 references indexed in Scilit:

• Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands
  Journal of Virology, 2002
• Adeno-Associated Virus Vector-Mediated Minidystrophin Gene Therapy Improves Dystrophic Muscle Contractile Function inmdxMice
  Human Gene Therapy, 2002
• Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy
  Gene Therapy, 2002
• Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1
  Gene Therapy, 2002
• An Adenovirus with Enhanced Infectivity Mediates Molecular Chemotherapy of Ovarian Cancer Cells and Allows Imaging of Gene Expression
  Molecular Therapy, 2001
• Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal Neovascularization
  Human Gene Therapy, 2001
• Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
  Nature Genetics, 2000
• Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
  Gene Therapy, 1999
• Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
  Gene Therapy, 1998
• Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR
  Biochemical and Biophysical Research Communications, 1996